The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, PhD, Professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute investigator, and Marcus E. Raichle, MD, Professor of Radiology and Neurology at Washington University School of Medicine in St. Louis. Both have been pioneers in the area of brain imaging leading to inroads in the study of Alzheimer's.
A new survey by MetLife Foundation finds that Alzheimer's disease is the second most feared disease among American adults, behind only cancer. When asked which of five major diseases they are most afraid, 31% said Alzheimer's, while 41% said cancer. Heart disease and stroke were named by 8% each, while only 6% said they fear diabetes most.
Their mission was to solve a small but nagging mystery of Alzheimer's disease: How would the brain's ability to store information be affected if they "turned off" the obscure protein LRP1?
But Guojun Bu and his fellow researchers were in for a surprise. As they expected, mice whose brains had been wiped of the LRP1 gene showed Alzheimer's-like memory problems. But they also started to put on weight - fast.
The mice were lethargic. They were on their way to becoming diabetic. And they didn't seem to know when to stop eating.
Scientists at the Harvard-affiliated Dana-Farber Cancer Institute say they have identified the root molecular cause of a variety of ills brought on by advanced age, including waning energy, failure of the heart and other organs, and metabolic disorders such as diabetes.
Invite your friends over, gather loved ones, serve some good munchies, and settle in for a night of TV well worth watching. Starting next Saturday, January 29, 2011, CNN will air a documentary film by Felipe Barral. It will focus the attention of viewers around the globe on the terrible scourge that is familial Alzheimer's disease. But more than that, it also showcases a wave of international momentum that is building among inspiring families, committed doctors, scientists - and hopefully industry and regulators - to stop the disease with prevention and therapeutic trials.
The launch of the International Genomics of Alzheimer's Project (IGAP) - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease - was announced today by a multi-national group of researchers. The collaborative effort, spanning universities from both Europe and the United States, will combine the knowledge, staff and resources of four consortia that conduct research on Alzheimer's disease genetics.
Researchers have been able to see changes deep within the brains of living animals at the cellular level. The advance could provide an important tool for understanding diseases and disorders of the brain, including substance abuse and addiction.
Facing the devastation of Alzheimer's disease, the normal forgetfulness of aging, or even just a particularly important exam, many people would be tempted by a drug that could prevent forgetting or enhance memory.
Pharmaceutical companies are racing to test compounds that could help treat people who suffer from devastating neurodegenerative diseases, while makers of nutritional supplements highlight their alledged brain-boosting abilites.
An advisory committee to the Food and Drug Administration recommended unanimously Thursday that the agency approve the first test - a brain scan - that can show the characteristic plaques of Alzheimer's disease in the brain of a living person. The approval was contingent on radiologists agreeing on what the scans say and doctors being trained in how to read the scans.